RecruitingNot Applicable

Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response

Canada26 participantsStarted 2026-07-07

Plain-language summary

This prospective, single-arm feasibility study will include patients with prostate cancer that have controlled local disease diagnosed with oligorecurrent para-aortic nodal disease and/or common iliac nodal disease detected by PSMA PET or conventional CT/MRI imaging, and these patients will undergo CT-guided online adaptive SBRT to the tumor and elective SBRT to adjacent at-risk nodal regions.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically confirmed prostate adenocarcinoma.
✓. Oligorecurrent para-aortic +/- common iliac nodal disease planned for SBRT.
✓. ≤10 involved para-aortic (defined as between L1/L2 interface and L4/L5 interface) +/- common iliac LN on PSMA PET imaging.
✓. ECOG performance status 0-2.

Exclusion criteria

✕. Prior radiotherapy to the nodal echelon (PA +/- common iliac).
✕. Active secondary malignancy, except for adequately treated non-melanoma skin cancer.
✕. Presence of significant comorbidities or medical conditions that may compromise the ability to undergo radiotherapy or participate in the study.
✕. Contraindication to radiation.

What they're measuring

Quantify adverse events using CTCAE v5.0

Timeframe: 2 years

Trial details

NCT IDNCT06831032

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-07-07

Contact for this trial

Andrew McPartlin, MD

416-946-4501 andrew.mcpartlin@uhn.ca

View on ClinicalTrials.gov More Prostate Adenocarcinoma trials